IL125124A0 - Dimeric forms of the protein fapalpha and uses thereof - Google Patents
Dimeric forms of the protein fapalpha and uses thereofInfo
- Publication number
- IL125124A0 IL125124A0 IL12512497A IL12512497A IL125124A0 IL 125124 A0 IL125124 A0 IL 125124A0 IL 12512497 A IL12512497 A IL 12512497A IL 12512497 A IL12512497 A IL 12512497A IL 125124 A0 IL125124 A0 IL 125124A0
- Authority
- IL
- Israel
- Prior art keywords
- protein
- fapalpha
- dimeric forms
- alpha
- dimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/619,280 US5767242A (en) | 1994-04-20 | 1996-03-18 | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| PCT/US1997/004215 WO1997034927A1 (en) | 1996-03-18 | 1997-03-12 | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL125124A0 true IL125124A0 (en) | 1999-01-26 |
Family
ID=24481231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12512497A IL125124A0 (en) | 1996-03-18 | 1997-03-12 | Dimeric forms of the protein fapalpha and uses thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US5767242A (bg) |
| EP (1) | EP0960127B1 (bg) |
| JP (1) | JP4102441B2 (bg) |
| KR (1) | KR20000064655A (bg) |
| CN (1) | CN1214052A (bg) |
| AT (1) | ATE449106T1 (bg) |
| AU (1) | AU729369B2 (bg) |
| BG (1) | BG102781A (bg) |
| BR (1) | BR9708100A (bg) |
| CA (1) | CA2242342C (bg) |
| CZ (1) | CZ299698A3 (bg) |
| DE (1) | DE69739665D1 (bg) |
| DK (1) | DK0960127T3 (bg) |
| EE (1) | EE03693B1 (bg) |
| ES (1) | ES2334183T3 (bg) |
| HU (1) | HUP0104468A3 (bg) |
| IL (1) | IL125124A0 (bg) |
| NO (1) | NO984298D0 (bg) |
| NZ (2) | NZ331758A (bg) |
| PL (1) | PL328947A1 (bg) |
| SK (1) | SK126798A3 (bg) |
| TR (1) | TR199801845T2 (bg) |
| WO (1) | WO1997034927A1 (bg) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| AU781897B2 (en) * | 1999-05-25 | 2005-06-23 | Point Therapeutics, Inc. | Anti-tumor comprising boroproline compounds |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| EP1806138A1 (en) * | 1999-05-25 | 2007-07-11 | Point Therapeutics, Inc. | Anti-tumor agents comprising boroproline compounds |
| US20030092890A1 (en) * | 1999-07-28 | 2003-05-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2005508838A (ja) * | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| KR20040049830A (ko) * | 2001-07-09 | 2004-06-12 | 애프톤 코포레이션 | 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방 |
| JP2005531540A (ja) | 2002-04-30 | 2005-10-20 | トラスティーズ・オブ・タフツ・カレッジ | セリンプロテアーゼ阻害剤のスマートプロドラッグ |
| JP2006506442A (ja) * | 2002-07-09 | 2006-02-23 | ポイント セラピューティクス， インコーポレイテッド | ボロプロリン化合物併用療法 |
| US20080057491A1 (en) * | 2003-02-07 | 2008-03-06 | Mckee Patrick A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use |
| US7309774B2 (en) | 2003-02-07 | 2007-12-18 | The Board Of Regents Of The University Of Oklahoma | Antiplasmin cleaving enzyme |
| US7235376B2 (en) * | 2003-03-28 | 2007-06-26 | Receptor Biologix, Inc. | Gastrin hormone immunoassays |
| WO2005071073A1 (en) * | 2004-01-09 | 2005-08-04 | Point Therapeutics, Inc. | Fap compositions and the use thereof for immunomodulation |
| JP5576592B2 (ja) * | 2004-03-29 | 2014-08-20 | キャンサー アドヴァンシズ インコーポレイテッド | ガストリンホルモンに対するモノクローナル抗体 |
| US20090010919A1 (en) * | 2004-07-29 | 2009-01-08 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap) |
| EP1794586B1 (en) | 2004-09-22 | 2013-01-30 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
| EP1812458A2 (en) * | 2004-10-27 | 2007-08-01 | Wen-Tien Chen | Methods and compositions for seprase inactivation |
| AU2005309443B2 (en) | 2004-11-24 | 2011-03-03 | Techlab, Inc. | Device and method for detection of analytes |
| US8067248B2 (en) | 2005-12-14 | 2011-11-29 | Luwig Institute for Cancer Research | Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| ES2393372T3 (es) * | 2006-06-21 | 2012-12-20 | The Scripps Research Institute | Composición de ADN contra el antígeno tumoral estromal FAP y métodos de utlización de la misma |
| WO2010099537A1 (en) | 2009-02-27 | 2010-09-02 | Trustees Of Tufts College | Soft protease inhibitors, and pro-soft forms thereof |
| CN113476616A (zh) | 2012-12-28 | 2021-10-08 | 科比欧尔斯公司 | 最低毒性的药物前体 |
| CN103267852B (zh) * | 2013-05-15 | 2015-03-25 | 中国医学科学院北京协和医院 | 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途 |
| CN113956325A (zh) | 2014-06-13 | 2022-01-21 | 塔夫茨大学信托人 | Fap激活的治疗剂以及其相关用途 |
| CN105859866B (zh) * | 2016-05-27 | 2019-08-13 | 郑州大学 | Fap来源的抗肿瘤ctl表位肽p265及其应用 |
| WO2018111989A1 (en) | 2016-12-14 | 2018-06-21 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| JP7469225B2 (ja) | 2017-06-15 | 2024-04-16 | キャンサー アドヴァンシーズ インク． | 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法 |
| AU2021405744A1 (en) | 2020-12-22 | 2023-08-03 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1320734C (en) * | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| US5587299A (en) * | 1994-04-20 | 1996-12-24 | Memorial Sloan-Kettering Cancer Center | Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof |
-
1996
- 1996-03-18 US US08/619,280 patent/US5767242A/en not_active Expired - Lifetime
-
1997
- 1997-03-12 EP EP97916024A patent/EP0960127B1/en not_active Expired - Lifetime
- 1997-03-12 ES ES97916024T patent/ES2334183T3/es not_active Expired - Lifetime
- 1997-03-12 TR TR1998/01845T patent/TR199801845T2/xx unknown
- 1997-03-12 EE EE9800306A patent/EE03693B1/xx not_active IP Right Cessation
- 1997-03-12 JP JP53359297A patent/JP4102441B2/ja not_active Expired - Fee Related
- 1997-03-12 SK SK1267-98A patent/SK126798A3/sk unknown
- 1997-03-12 IL IL12512497A patent/IL125124A0/xx unknown
- 1997-03-12 CA CA2242342A patent/CA2242342C/en not_active Expired - Fee Related
- 1997-03-12 CN CN97193176A patent/CN1214052A/zh active Pending
- 1997-03-12 AT AT97916024T patent/ATE449106T1/de active
- 1997-03-12 CZ CZ982996A patent/CZ299698A3/cs unknown
- 1997-03-12 KR KR1019980707369A patent/KR20000064655A/ko not_active Application Discontinuation
- 1997-03-12 AU AU23302/97A patent/AU729369B2/en not_active Ceased
- 1997-03-12 WO PCT/US1997/004215 patent/WO1997034927A1/en not_active Application Discontinuation
- 1997-03-12 NZ NZ331758A patent/NZ331758A/xx unknown
- 1997-03-12 HU HU0104468A patent/HUP0104468A3/hu unknown
- 1997-03-12 BR BR9708100-0A patent/BR9708100A/pt not_active Application Discontinuation
- 1997-03-12 DE DE69739665T patent/DE69739665D1/de not_active Expired - Lifetime
- 1997-03-12 PL PL97328947A patent/PL328947A1/xx unknown
- 1997-03-12 DK DK97916024.9T patent/DK0960127T3/da active
- 1997-10-01 US US08/940,391 patent/US5965373A/en not_active Expired - Lifetime
-
1998
- 1998-09-17 NO NO984298A patent/NO984298D0/no not_active Application Discontinuation
- 1998-09-18 BG BG102781A patent/BG102781A/bg unknown
-
1999
- 1999-05-03 NZ NZ335543A patent/NZ335543A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4102441B2 (ja) | 2008-06-18 |
| NO984298L (no) | 1998-09-17 |
| CA2242342C (en) | 2013-05-14 |
| BG102781A (bg) | 1999-09-30 |
| NO984298D0 (no) | 1998-09-17 |
| AU2330297A (en) | 1997-10-10 |
| US5767242A (en) | 1998-06-16 |
| DK0960127T3 (da) | 2010-03-29 |
| BR9708100A (pt) | 2000-01-04 |
| DE69739665D1 (de) | 2009-12-31 |
| SK126798A3 (en) | 1999-05-07 |
| EP0960127A1 (en) | 1999-12-01 |
| US5965373A (en) | 1999-10-12 |
| ATE449106T1 (de) | 2009-12-15 |
| AU729369B2 (en) | 2001-02-01 |
| CN1214052A (zh) | 1999-04-14 |
| EP0960127A4 (en) | 2004-09-08 |
| EE9800306A (et) | 1999-02-15 |
| TR199801845T2 (xx) | 1998-12-21 |
| PL328947A1 (en) | 1999-03-01 |
| ES2334183T3 (es) | 2010-03-05 |
| JP2000507100A (ja) | 2000-06-13 |
| WO1997034927A1 (en) | 1997-09-25 |
| EE03693B1 (et) | 2002-04-15 |
| HUP0104468A2 (hu) | 2002-04-29 |
| HUP0104468A3 (en) | 2004-10-28 |
| CA2242342A1 (en) | 1997-09-25 |
| EP0960127B1 (en) | 2009-11-18 |
| NZ335543A (en) | 2001-03-30 |
| NZ331758A (en) | 2000-01-28 |
| KR20000064655A (ko) | 2000-11-06 |
| CZ299698A3 (cs) | 1999-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL125124A0 (en) | Dimeric forms of the protein fapalpha and uses thereof | |
| ATE280826T1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| YU15299A (sh) | Farmaceutski sastavi | |
| EP2295453A3 (en) | An appetite-suppressing peptide, its compositions and use | |
| EP0960107A4 (bg) | ||
| DE69534778D1 (en) | Cathepsin-02-protease | |
| GR970300016T1 (en) | Lactobacillus strains of human origin, their compositions and uses thereof | |
| NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
| IL127918A0 (en) | Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations | |
| AU5186799A (en) | Peptides of il-2 and derivatives thereof and their use as therapeutic agents | |
| AR016981A2 (es) | Polipeptidos sinteticos | |
| BG103968A (bg) | Противовирусен фармацевтичен състав | |
| HK1001404A1 (en) | Isolated, tyrosinase derived peptides and uses thereof. | |
| TR199901190T2 (xx) | Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler. | |
| PT929299E (pt) | 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos | |
| BG101787A (bg) | Апротининови варианти с подобрени свойства | |
| PE20399A1 (es) | Muteina ob | |
| BG102937A (bg) | Зона пелуцида протеини като контрацептиви | |
| ZA978233B (en) | The use of protein as anti-retroviral agents. | |
| MX9800981A (es) | Promotor del gen de endoglina humana y su uso. |